Bluejay Diagnostics (NASDAQ:BJDX) Major Shareholder Financial Lp Hrt Buys 64,047 Shares of Stock

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) major shareholder Financial Lp Hrt acquired 64,047 shares of the firm’s stock in a transaction on Thursday, July 9th. The stock was purchased at an average cost of $1.51 per share, for a total transaction of $96,710.97. Following the completion of the acquisition, the insider owned 126,993 shares in the company, valued at approximately $191,759.43. This represents a 101.75% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Friday, July 10th, Financial Lp Hrt sold 34,938 shares of Bluejay Diagnostics stock. The stock was sold at an average price of $1.40, for a total value of $48,913.20.

Bluejay Diagnostics Stock Down 15.9%

Shares of BJDX traded down $0.23 during midday trading on Monday, reaching $1.22. 973,437 shares of the stock were exchanged, compared to its average volume of 1,803,857. Bluejay Diagnostics, Inc. has a twelve month low of $1.03 and a twelve month high of $16.68. The company has a market cap of $1.26 million, a P/E ratio of -0.10 and a beta of 0.88. The stock’s 50 day simple moving average is $2.69 and its 200 day simple moving average is $2.49.

Bluejay Diagnostics (NASDAQ:BJDX) last released its quarterly earnings results on Thursday, May 7th. The company reported ($1.95) EPS for the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Bluejay Diagnostics in a research report on Wednesday, June 24th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Bluejay Diagnostics presently has an average rating of “Sell”.

Institutional Trading of Bluejay Diagnostics

An institutional investor recently bought a new position in Bluejay Diagnostics stock. Armistice Capital LLC acquired a new position in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned 9.15% of Bluejay Diagnostics as of its most recent SEC filing. Institutional investors and hedge funds own 18.47% of the company’s stock.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.